EUVIMEDEUVIMED entdecken
Übersichtsarbeit

2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas

Jochen Bauer iD, Heiner N Raum iD, Harald Kugel iD, Michael Müther, Manoj Mannil, Walter Heindel iD

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 01.12.2024 · 196 (12) · 1228-1235

DOI: 10.1055/a-2285-4923 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, erschienen am 01.12.2024. Verfasst von Jochen Bauer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Glutarates, Isocitrate Dehydrogenase, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mutated enzyme isocitrate dehydrogenase (IDH) 1 and 2 has been detected in various tumor entities such as gliomas and can convert α-ketoglutarate into the oncometabolite 2-hydroxyglutarate (2-HG). This neuro-oncologically significant metabolic product can be detected by MR spectroscopy and is therefore suitable for noninvasive glioma classification and therapy monitoring. This paper provides an up-to-date overview of the methodology and relevance of 1H-MR spectroscopy (MRS) in the oncological primary and follow-up diagnosis of gliomas. The possibilities and limitations of this MR spectroscopic examination are evaluated on the basis of the available literature. By detecting 2-HG, MRS can in principle offer a noninvasive alternative to immunohistological analysis thus avoiding surgical intervention in some cases. However, in addition to an adapted and optimized examination protocol, the individual measurement conditions in the examination region are of decisive importance. Due to the inherently small signal of 2-HG, unfavorable measurement conditions can influence the reliability of detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutaratesIsocitrate DehydrogenaseGliomaBrain NeoplasmsMutationHumansMagnetic Resonance SpectroscopyBiomarkers, TumorSensitivity and Specificity

Substanzen

GlutaratesIsocitrate Dehydrogenasealpha-hydroxyglutarateIDH1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Clinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany.
  • Department of Neurosurgery, University of Münster and University Hospital Münster, Münster, Germany.
  • Institute for Diagnostic and Interventional Radiology, Caritas Hospital Bad Mergentheim, Bad Mergentheim, Germany.

ORCID-Profile: Jochen Bauer, Heiner N Raum, Harald Kugel, Walter Heindel

Zitieren

APA

Bauer, J., Raum, H. N., Kugel, H., Müther, M., Mannil, M., & Heindel, W. (2024). 2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 196(12), 1228-1235. https://doi.org/10.1055/a-2285-4923

Vancouver

Bauer J, Raum HN, Kugel H, Müther M, Mannil M, Heindel W. 2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2024;196(12):1228-1235. doi:10.1055/a-2285-4923

BibTeX
@article{Bauer2024,
  author = {Bauer, Jochen and Raum, Heiner N and Kugel, Harald and Müther, Michael and Mannil, Manoj and Heindel, Walter},
  title = {2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas},
  journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
  year = {2024},
  volume = {196},
  number = {12},
  pages = {1228--1235},
  doi = {10.1055/a-2285-4923}
}
Kostenlos starten →